AB-101 is a special treatment made from "natural killer" cells, a type of white blood cell that fights cancer. This study is for patients with a type of cancer called non-Hodgkin lymphoma (NHL) that has come back, known as relapsed/refractory. The study has two phases. In Phase 1, researchers will check if AB-101 is safe to use alone or with other treatments like rituximab (a medicine used to treat certain types of cancer) and bendamustine (a chemotherapy drug). They will also find the best dose for Phase 2, where they will see if AB-101 can help fight cancer. Patients will get AB-101 alone or with rituximab or with both bendamustine and rituximab. They will have regular health checks and tests to see if the treatment is helping. Some patients might receive up to 5 cycles of treatment.

• The study involves regular health checks and tests to monitor progress.
• Patients could receive 1 to 5 cycles of treatment, depending on the combination.
• Eligibility includes having specific types of NHL and previous treatments.